CN103412064A - Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph - Google Patents

Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph Download PDF

Info

Publication number
CN103412064A
CN103412064A CN2013103164314A CN201310316431A CN103412064A CN 103412064 A CN103412064 A CN 103412064A CN 2013103164314 A CN2013103164314 A CN 2013103164314A CN 201310316431 A CN201310316431 A CN 201310316431A CN 103412064 A CN103412064 A CN 103412064A
Authority
CN
China
Prior art keywords
impurity
high performance
performance liquid
chlorobenzene glycine
liquid chromatography
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2013103164314A
Other languages
Chinese (zh)
Other versions
CN103412064B (en
Inventor
许学农
黄栋梁
范红
包志坚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Lixin Pharmaceutical Co., Ltd.
Original Assignee
SUZHOU LIXIN PHARMACY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU LIXIN PHARMACY CO Ltd filed Critical SUZHOU LIXIN PHARMACY CO Ltd
Priority to CN201310316431.4A priority Critical patent/CN103412064B/en
Publication of CN103412064A publication Critical patent/CN103412064A/en
Application granted granted Critical
Publication of CN103412064B publication Critical patent/CN103412064B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention discloses a method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph. The method specifically comprises the following steps: (1), determining that the chromatographic column is c18/250*4.6mm/5 mmu m, the column temperature is 30 DEG C, the wavelength is 254 nm, the flow rate is 0.8 mL/min, and the sample size is 10 mmu L; (2) mobile phase A detection: mixing 20 mmol/L of potassium dihydrogen phosphate solution with the volume of 95% and methanol with the volume of 5%, adjusting the pH value to be 2.5 with phosphate; and mobile phase B detection: mixing acetonitrile with the volume of 50% and methanol with the volume of 50%; (3) measuring and recording chromatogram. Through the method provided by the invention, all impurities of DL-2-Chlorophenylglycine, in particular to chlorobenzene glycine (impurity B) and 0-chlorphenyl glycinamide (impurity C), can be better separated, and the repeatability is good; the successful development of the method has important realistic significance in raw material control and quality assurance in production of bulk drug of clopidogrel.

Description

By high performance liquid chromatography, detect the method for o-chlorobenzene glycine impurity
Technical field
The invention belongs to the organic analysis technical field, particularly a kind of method that detects the o-chlorobenzene glycine impurities of one of clopidogrel raw materials by high performance liquid chromatography.
Background technology
Bisulfate clopidogrel (Clopidogrel Hydrogensulfate) is the RA233 of new generation of being succeeded in developing in 1986 by French Sai Nuofei (Sanofi) company, can be used for prevention of arterial atherosis and the treatment acute myocardial infarction AMI, commodity are called " Plavix ".This product took the lead in, in U.S. listing, entering subsequently the multinational markets such as Europe, North America, Australia, Singapore in March, 1998, and August calendar year 2001 at Discussion on Chinese Listed.It belongs to the Thienopyridines medicine, is a kind of novel adenosine diphosphate (ADP) receptor antagonist, because have good security and suppress fast hematoblastic advantage, becomes one of antiplatelet drug of widespread use thereby replaced ticlopidine.
The preparation method of clopidogrel has a variety of, and the o-chlorobenzene glycine (S) of wherein take is the reactions steps such as esterification, fractionation, condensation, cyclization and salify as the synthetic route of initiation material.
Figure BDA00003566720100011
In order to improve the quality of pharmaceutical production, according to pharmaceutical production standard and product standard, as the regulation of American Pharmacopeia (USP) and European Pharmacopoeia (EP), need to carry out effective analysis and control to the quality of primary raw material o-chlorobenzene glycine (S).Analyze preparation and the degradation process of o-chlorobenzene glycine, several impurity compositions that may exist are:
Figure BDA00003566720100021
Current, analyze and detect o-chlorobenzene glycine (S) and mostly by efficient liquid-phase chromatography method, realize, its chromatographic process is generally: chromatographic column (C18/250 * 4.6mm/5 μ m), column temperature (25 ℃), wavelength (254nm), flow velocity (1.0mL/min) and sample size (20 μ L); Selected mobile phase is: water/acetonitrile/tetrahydrochysene furan (85/9/6), and wherein water is the aqueous dibasic potassium phosphate solution 800mL of 20mmol/L, hydrochloric acid is adjusted to pH=2.5, and to be diluted to volume be 1000mL.
Detect according to the method described above substrate o-chlorobenzene glycine (S) sample that contains p-chlorophenylglycine (impurity B) and adjacent chlorobenzene glycine amide (impurity C), discovery can only show an impurity peaks, and namely impurity B can not be separated (seeing Fig. 1) well with C under this testing conditions.
In order to verify the above results, reference substance mixing sample introduction by p-chlorophenylglycine (impurity B) and adjacent chlorobenzene glycine amide (impurity C), the result obtained still is unimodal (seeing Fig. 2), further proved thus the high-efficiency liquid chromatography method for detecting of current general o-chlorobenzene glycine (S), for impurity, separate, especially for p-chlorophenylglycine (impurity B) and separating of adjacent chlorobenzene glycine amide (impurity C) having major defect, even under this system, can't effectively isolate these two impurity.
Summary of the invention
In order to overcome the defect of prior art, the object of the present invention is to provide a kind of improved high performance liquid chromatography that utilizes to detect the method for preparing clopidogrel raw material o-chlorobenzene glycine (S) impurities.This detection method can be separated the plurality of impurities of o-chlorobenzene glycine (S) effectively, particularly realizes efficient separation of p-chlorophenylglycine (impurity B) and adjacent chlorobenzene glycine amide (impurity C).
To achieve these goals, the present invention mainly provides following technical scheme: a kind of method that detects o-chlorobenzene glycine impurity by high performance liquid chromatography is characterized in that described detection method comprises the steps: (1) selection definite chromatographic column, column temperature, wavelength, flow velocity and sample size; (2) preparation mobile phase definite gradient program; And chromatogram is measured and recorded in (3).
In addition, the present invention also comprises following attached technical scheme:
Described chromatographic column is C18/250 * 4.6mm/5 μ m.
Described column temperature 30-50 ℃, preferably 30 ℃.
Described mensuration wavelength is 245-260nm, preferably 254nm.
Described flow velocity is 0.5-1.5mL/min, preferably 0.8mL/min.
Described mobile phase A is after the potassium dihydrogen phosphate of the 20mmol/L of 90-99% volume mixes with the methyl alcohol of 10-1% volume, to use phosphoric acid adjust pH to 2.5, and preferably the potassium dihydrogen phosphate of the 20mmol/L of 95% volume is used phosphoric acid adjust pH to 2.5 after with the methyl alcohol of 5% volume, mixing.
Described Mobile phase B is 25-75% volumes of acetonitrile and 75-25% volumes methanol, preferably 50% volumes of acetonitrile and 50% volumes methanol.
The gradient time-program(me) of described mobile phase is 100%-0%/0-40min.
Than prior art, the involved in the present invention high performance liquid chromatography that utilizes detects the method for o-chlorobenzene glycine (S) impurities of one of clopidogrel raw materials.This detection method can be separated the impurity of o-chlorobenzene glycine effectively, particularly realize efficient separation of p-chlorophenylglycine (impurity B) and adjacent chlorobenzene glycine amide (impurity C), the method degree of separation is high, favorable reproducibility, has important practical significance for the control of the raw material in the clopidogrel production of raw medicine and quality assurance.
The accompanying drawing explanation
Fig. 1 measures the high-efficient liquid phase chromatogram of the o-chlorobenzene glycine (S) that contains impurity B and C according to a kind of traditional detection method
Fig. 2 measures the high-efficient liquid phase chromatogram of impurity B and impurity C reference substance potpourri according to another kind of traditional detection method.
Fig. 3 is the gradient time-program(me) corresponding to the mobile phase of detection method of the present invention.
Fig. 4 measures the high-efficient liquid phase chromatogram of the o-chlorobenzene glycine (S) that contains impurity B and C according to detection method of the present invention.
Fig. 5 measures the high-efficient liquid phase chromatogram of impurity B and impurity C reference substance potpourri according to detection method of the present invention.
Fig. 6 measures the high-efficient liquid phase chromatogram of the o-chlorobenzene glycine (S) that contains impurity A, B, C, D, E and F according to the inventive method.
Embodiment
Below will set forth the impurity that how detects o-chlorobenzene glycine by high performance liquid chromatography by several concrete testing processes and spectrogram.
(1) chromatographic condition
Chromatographic column: C18,250 * 4.6mm, 5 μ m
Column temperature: 30 ℃
Wavelength: 254nm
Flow velocity: 0.8mL/min
Sample size: 10 μ L
(2) mobile phase
Mobile phase A: the potassium dihydrogen phosphate of the 20mmol/L of 95% volume, the methyl alcohol of 5% volume, use phosphoric acid adjust pH to 2.5 after mixing.Mobile phase B: the methyl alcohol of the acetonitrile of 50% volume and 50% volume.
The gradient time-program(me) can be referring to Fig. 3.
(3) record collection of illustrative plates
Embodiment mono-:
With reference to Fig. 4, in o-chlorobenzene glycine (S), contain p-chlorophenylglycine (impurity B) and adjacent chlorobenzene glycine amide (impurity C).
Embodiment bis-:
With reference to Fig. 5, impurity reference substance checking: p-chlorophenylglycine (impurity B) and adjacent chlorobenzene glycine amide (impurity C).
Embodiment tri-:
With reference to Fig. 6, contain impurity A, B, C, D, E and F in o-chlorobenzene glycine (S).
It is pointed out that above-mentioned preferred embodiment only is explanation technical conceive of the present invention and characteristics, its purpose is to allow the person skilled in the art can understand content of the present invention and implement according to this, can not limit the scope of the invention with this.All equivalences that Spirit Essence is done according to the present invention change or modify, within all should being encompassed in protection scope of the present invention.

Claims (8)

1. a method that detects o-chlorobenzene glycine impurity by high performance liquid chromatography, is characterized in that described detection method comprises the steps:
(1) selection definite chromatographic column, column temperature, wavelength, flow velocity and sample size;
(2) preparation mobile phase definite gradient program; And
(3) measure and record chromatogram.
2. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: described chromatographic column is C18/250 * 4.6mm/5 μ m.
3. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: described column temperature 30-50 ℃.
4. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: described mensuration wavelength is 245-260nm.
5. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: described flow velocity is 0.5-1.5mL/min.
6. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: described mobile phase A is with phosphoric acid adjust pH to 2.5 after the potassium dihydrogen phosphate of the 20mmol/L of 90-99% volume mixes with the methyl alcohol of 10-1% volume.
7. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: described Mobile phase B is 25-75% volumes of acetonitrile and 75-25% volumes methanol.
8. by high performance liquid chromatography, detect according to claim 1 the method for o-chlorobenzene glycine impurity, it is characterized in that: the gradient time-program(me) of described mobile phase is 100%-0%/0-40min.
CN201310316431.4A 2013-07-25 2013-07-25 Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph Active CN103412064B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310316431.4A CN103412064B (en) 2013-07-25 2013-07-25 Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310316431.4A CN103412064B (en) 2013-07-25 2013-07-25 Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph

Publications (2)

Publication Number Publication Date
CN103412064A true CN103412064A (en) 2013-11-27
CN103412064B CN103412064B (en) 2015-05-20

Family

ID=49605090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310316431.4A Active CN103412064B (en) 2013-07-25 2013-07-25 Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph

Country Status (1)

Country Link
CN (1) CN103412064B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106220634A (en) * 2016-08-03 2016-12-14 苏州立新制药有限公司 Related substances F and G of pemetrexed disodium and preparation thereof and detection method
CN106596799A (en) * 2017-01-20 2017-04-26 阳泉煤业(集团)有限责任公司 Method for detecting glycine and impurities thereof by high performance liquid chromatography
CN108760940A (en) * 2018-08-03 2018-11-06 安徽省金楠医疗科技有限公司 A kind of bisulfate clopidogrel detection method
CN114689737A (en) * 2021-12-31 2022-07-01 浙江车头制药股份有限公司 Analysis method of S-o-chlorophenyl glycine methyl ester tartrate related substances

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094006A1 (en) * 2006-02-13 2007-08-23 Lee Pharma Limited Process for preparation of clopidogrel bisulfate form 1
CN101393185A (en) * 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 Method for analytically separating clopidogrel and enantiomer thereof by HPLC method
US20110087028A1 (en) * 2008-06-09 2011-04-14 Enzytech Ltd. Method for preparing clopidogrel and its derivatives
CN103185750A (en) * 2011-12-31 2013-07-03 深圳信立泰药业股份有限公司 Mass control method for clopidogrel splitting agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094006A1 (en) * 2006-02-13 2007-08-23 Lee Pharma Limited Process for preparation of clopidogrel bisulfate form 1
CN101393185A (en) * 2007-09-21 2009-03-25 北京德众万全药物技术开发有限公司 Method for analytically separating clopidogrel and enantiomer thereof by HPLC method
US20110087028A1 (en) * 2008-06-09 2011-04-14 Enzytech Ltd. Method for preparing clopidogrel and its derivatives
CN103185750A (en) * 2011-12-31 2013-07-03 深圳信立泰药业股份有限公司 Mass control method for clopidogrel splitting agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
孙毓庆: "《液相色谱溶剂系统的选择与优化》", 31 January 2008, 北京化工出版社 *
徐亚荣: "《苯甘氨酸、对氯苯甘氨酸合成工艺的研究》", 《中国优秀博硕士学位论文全文数据库》 *
杨扬等: "合成法生产对氯苯甘氨酸的RP-HPLC测定", 《江苏石油化工学院学报》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106220634A (en) * 2016-08-03 2016-12-14 苏州立新制药有限公司 Related substances F and G of pemetrexed disodium and preparation thereof and detection method
CN106596799A (en) * 2017-01-20 2017-04-26 阳泉煤业(集团)有限责任公司 Method for detecting glycine and impurities thereof by high performance liquid chromatography
CN108760940A (en) * 2018-08-03 2018-11-06 安徽省金楠医疗科技有限公司 A kind of bisulfate clopidogrel detection method
CN114689737A (en) * 2021-12-31 2022-07-01 浙江车头制药股份有限公司 Analysis method of S-o-chlorophenyl glycine methyl ester tartrate related substances
CN114689737B (en) * 2021-12-31 2023-12-08 浙江车头制药股份有限公司 Analysis method of S-o-chlorophenylglycine methyl tartrate related substances

Also Published As

Publication number Publication date
CN103412064B (en) 2015-05-20

Similar Documents

Publication Publication Date Title
CN108780075A (en) The high-sensitivity analysis method of Imatinib gene impurity
CN103412064B (en) Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph
CN104914185A (en) HPLC method for measuring related substances in Favipiravir
CN104965041A (en) High performance liquid chromatography detection method for parecoxib sodium isomer
CN106153798B (en) It is a kind of to be used to analyze the purposes for doing reference standard about the HPLC methods and these impurity of material for Buddhist nun's preparation according to Shandong for Buddhist nun and according to Shandong
CN109212048A (en) The detection method of impurity content in a kind of voriconazole
CN105388225A (en) Analysis and detection method for UDPC in medicinal preparation containing citicoline sodium
CN106153797B (en) It is a kind of to replace Buddhist nun's preparation Related substance method according to Shandong for Buddhist nun and according to Shandong
CN106093233A (en) The assay method of content of isomer in esomeprazole sodium freeze-dried powder injection
CN105866263B (en) A kind of method of quality control of Fasudic hydrochloride
CN107525877B (en) Method for separating and determining brexpiprazole and impurities thereof by adopting liquid chromatography
CN103926335B (en) The high-efficient liquid phase chromatogram process measuring method of related substance in a kind of Dapoxetine hydrochloride
CN103134886A (en) Method for analytical separation sodium ibandronate and impurities thereof by utilizing high performance liquid chromatography (HPLC)
CN108169362B (en) Method for separating carbamazepine and related substances by liquid chromatography
CN104764840B (en) The separation of palonosetron Hcl and impurity and detection method
CN104359993B (en) A kind of detection method of ambrisentan related substance
CN103575814A (en) Detecting method for 5 flavones and 4 alkaloids in blood plasma
CN105181859A (en) Cysteine hydrochloride in acetaminophen injection and test method of degradation product cystine
Wang et al. Detection of two genotoxic impurities in drug substance and preparation of imatinib mesylate by LC–MS/MS
CN105004803A (en) Liquid chromatographic method for separating and determining multiple impurities in tolvaptan
CN105319288A (en) Method for separating and measuring bilastine and technical impurities in preparation of bilastine
CN103995062B (en) Method for testing exenatide and impurities thereof by using high performance liquid chromatography
CN114778711A (en) Method for analyzing related substances of sulfadoxine
CN107677751A (en) A kind of method of high performance liquid chromatography detection Amlodipine Besylate Tablet and its impurity
CN104374861B (en) The method of the related substance of the western croak bulk drug of a kind of HPLC separation determination Leo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190308

Address after: 255000 Jinyang Road, Gaoqing Economic Development Zone, Zibo City, Shandong Province

Patentee after: Shandong Lixin Pharmaceutical Co., Ltd.

Address before: 215151 No. 21 Tangxi Road, Suzhou High-tech Zone, Jiangsu Province

Patentee before: Suzhou Lixin Pharmacy Co., Ltd.

PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Method for detecting impurities of DL-2-Chlorophenylglycine through high performance liquid chromatograph

Effective date of registration: 20190422

Granted publication date: 20150520

Pledgee: Hengfeng Bank Co., Ltd. Zibo Branch

Pledgor: Shandong Lixin Pharmaceutical Co., Ltd.

Registration number: 2019370000082

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20201111

Granted publication date: 20150520

Pledgee: Hengfeng Bank Co.,Ltd. Zibo Branch

Pledgor: Shandong Lixin Pharmaceutical Co.,Ltd.

Registration number: 2019370000082